CoChat

Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development

Open access
Regev, Arie, Avigan, Mark I., Kiazand, Alexandre, Vierling, John M., Lewis, James H., Omokaro, Stephanie O., Di Bisceglie, Adrian M., Fontana, Robert J., Bonkovsky, Herbert L., Freston, James W., Uetrecht, Jack P., Miller, Ethan D., Pehlivanov, Nonko D., Haque, Syed Asif, Harrison, Melanie J., Kullak-Ublick, Gerd A., Li, Hewei, Patel, Niti N., Patwardhan, Meenal, Price, Karen D., Watkins, Paul B., Chalasani, Naga P. · 2020 · Journal of Autoimmunity
Cited by 83

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various malignancies, however, they are associated with a wide range of immune-related toxicities affecting many organs, including the liver. Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) is a distinctive form of drug induced liver injury (DILI), that differs from most DILI types in presumed underlying mechanism, incidence, and response to therapeutic interventions. Despite increased awareness of ILICI and other immune-related adverse effects of ICIs reflected by recent guidelines for their management in post marketing clinical practice, there is lack of uniform best practices to address ILICI risk during drug development. As efforts to develop safer and more effective ICIs for additional indications grow, and as combination therapies including ICIs are increasingly investigated, there is a growing need for consistent practices for ILICI in drug development. This publication summarizes current best practices to optimize the monitoring, diagnosis, assessment, and management of suspected ILICI in clinical trials using ICI as a single agent and in combination with other ICIs or other oncological agents. It is one of several publications developed by the IQ DILI Initiative in collaboration with DILI experts from academia and regulatory agencies. Recommended best practices are outlined pertaining to hepatic inclusion and exclusion criteria, monitoring of liver tests, ILICI detection, approach to a suspected ILICI signal, causality assessment, hepatic discontinuation rules and additional medical treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaut.2020.102514

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 83

Metadata

Authors
Regev, A., Avigan, M. I., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Di Bisceglie, A. M., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., Uetrecht, J. P., Miller, E. D., Pehlivanov, N. D., Haque, S. A., Harrison, M. J., Kullak-Ublick, G. A., Li, H., Patel, N. N., Patwardhan, M., Price, K. D., Watkins, P. B., & Chalasani, N. P.
Venue
Journal of Autoimmunity
Publisher
Elsevier BV
Published
2020-11
Volume
114
Pages
102514
ISSN
0896-8411 (ISSN-L)
OpenAlex
W3046923728
Cited by
83
References
33
FWCI
2.49
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.